title: Veno-occlusive disease in pediatric patients after hematopoietic stem cell transplantation: relevance of activated coagulation and fibrinolysis markers and natural anticoagulants.
abstract: Prediction of veno-occlusive disease (VOD), its precise diagnosis, and treatment have been the subject of various studies, but still remain unclear. Our goal was to investigate the levels of activated coagulation and fibrinolysis markers and natural anticoagulants in pediatric patients with VOD after hematopoietic stem cell transplantation (HSCT). We investigated 47 pediatric patients: 20 with neuroblastoma, 17 with leukemias, and 10 with lymphomas and measured the values of antithrombin (AT), protein C (PC), fibrinogen (FI), thrombin AT complex, prothrombin fragments 1+2 (F1+2), and D-dimer from day -7 to day +30 post-HSCT. Patients were monitored for the occurrence of VOD, and it occurred in 10 patients at a median post-HSCT day of 17.5 (range: 2 to 28 d). In the VOD group, at baseline the levels of FI were significantly lower, and on days +7 and +14 a relevant difference existed in F1+2 levels. The levels of PC were significantly lower on day +14. Logistic multivariate regression analysis between the groups showed significantly different D-dimer levels on day +14. On day +30, the levels of PC, AT, and F1+2 were different between these 2 groups of patients. The levels of D-dimer and F1+2 were increased, and PC and FI decreased before the clinical onset of VOD. The parameter differences may have a predictive value in VOD onset, which makes them candidates to be routinely monitored in patients after HSCT.
authors.affiliation: Bone Marrow Transplantation Unit and Coagulation Laboratory, Mother and Child Health Care Institute of Serbia Dr Vukan Cupic, Institute for Statistics, University of Belgrade, Belgrade, Serbia. drjevtic@beotel.rs
authors.forename: Dragana
authors.initials: D
authors.lastname: Jevtic
authors.forename: Zeljko
authors.initials: Z
authors.lastname: Zecevic
authors.forename: Dobrila
authors.initials: D
authors.lastname: Veljkovic
authors.forename: Violeta
authors.initials: V
authors.lastname: Dopsaj
authors.forename: Zoran
authors.initials: Z
authors.lastname: Radojicic
authors.forename: Ivo
authors.initials: I
authors.lastname: Elezovic
mesh_terms: D000293:Adolescent; D000925:Anticoagulants / Q000097:blood*; D001777:Blood Coagulation; D002648:Child; D002675:Child, Preschool; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005342:Fibrinolysis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006504:Hepatic Veno-Occlusive Disease / Q000097:blood / Q000209:etiology*; D006801:Humans; D007223:Infant; D008297:Male; D019172:Transplantation Conditioning
chemical_list: D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D